Abstract 272P
Background
5-fluorouracil (5-FU) is a major component of chemotherapy regimens in gastrointestinal (GI) cancers. Mutation in Dihydropyrimidine Dehydrogenase (DPD) gene can cause severe 5-FU related toxicity. Identifying the mutation helps in predicting the toxicity and adjusting dose of 5-FU. Our study assesses and analyze the utility of DPD testing at our center.
Methods
Data of GI cancer patients who has been tested for DPD enzyme while planning chemotherapy (for both adjuvant and palliative settings) was extracted from our center’s electronic records from the 1st June 2016 to 31st December 2021 and evaluated. We collected demographics of the patients, genotypes of DPD gene, disease status, chemotherapy type and the associated toxicities.
Results
Total 211 patients were tested for the DPD gene with median age of 66 years (Female=78). 120 patients were found to have mutation. There were 6 different DPD genotypes in our dataset. Among mutated ones, 36% were female. Seven patients were homozygous for some DPD gene variants, most common was *9A (c.85 T>C; p.C29R) genotype. While 2 out of 7 had severe diarrhea (Grade 3/4, CTCAE V.5) during chemotherapy, no patient died of toxicity. Among mutated vs non-mutated patients, grade 3/4 diarrhoea was 25% vs 38% (Chi Sq (1, N = 65) = 4.39, p = .035), anemia was 10% vs 9% (Chi Sq (1, N=21) = 0.0007, p= .978), neutropenia was 9% vs 4% (Chi Sq (1, N=15) =1.78, p= .181), thrombocytopenia was 5% vs 3% (Chi Sq (1, N=9) = 0.36, p= .544), mucositis was 6% vs 1% (Chi Sq (1, N=9) = 3.92, p= .047). Most patients with Grade 3/4 toxicity were on combination chemotherapy. We found 9 different DPD genotypes in our population. Among them, *9A (c.85 T>C; p.C29R) caused most severe GI toxicity, *2A (c.14+1 G>A) genotype resulted in severe hematological and GI toxicity. We lost one patient to toxicity having heterozygous *6 (2194 G/A; p.V732I) mutation.
Conclusions
DPD gene testing can help in predicting the toxicity to 5-FU based chemotherapy. We found that diarrhea and mucositis were related to the DPD gene mutation more than anemia, neutropenia and thrombocytopenia. Genotype analysis should be an important part of the treatment plan for GI cancers.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Tanuj Chawla.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
150P - Use of neoadjuvant chemotherapy for non-metastatic muscle-invasive bladder cancer in Asia-Pacific
Presenter: Ravindran Kanesvaran
Session: Poster viewing 03
Resources:
Abstract
Slides
151P - Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer: Real-world analysis of chemotherapy use and impact on patient outcomes
Presenter: Alison Hiong
Session: Poster viewing 03
152P - An epidemiologic study on PD-L1 expression with clinical observation of initial treatment pattern in the Chinese muscle invasive urothelial bladder carcinoma patients
Presenter: Liqun Zhou
Session: Poster viewing 03
153P - Efficacy and toxicity of HER2-targeted antibody-drug conjugates (ADCs) in the treatment of metastatic urothelial cancer (mUC): A systematic review
Presenter: Tiago Padua
Session: Poster viewing 03
154P - Can urine cytology predict variants of bladder cancer?
Presenter: Hikaru Mikami
Session: Poster viewing 03
155P - Search for circulating tumor cells in patients with urothelial cancer
Presenter: Irina Kruglova
Session: Poster viewing 03
156P - The association between response to enfortumab vedotin therapy and primary tumor location in Japanese urothelial carcinoma patients
Presenter: Nozomi Hayakawa
Session: Poster viewing 03
163P - Outcomes and toxicity of fosfesterol in metastatic castration-resistant prostate cancer: Experience from a low middle income country
Presenter: Manuprasad Avaronnan
Session: Poster viewing 03
164P - F-18 PSMA-PET/CT-guided percutaneous prostate biopsy
Presenter: Rajender Kumar
Session: Poster viewing 03
165P - Real-world utilisation of upfront chemohormonal therapy in metastatic hormone-sensitive prostate cancer
Presenter: Richard Kelly
Session: Poster viewing 03